The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== Proneurogenic function of alpha-synuclein === In some neurodegenerative diseases, alpha-synuclein produces insoluble inclusion bodies. These diseases, known as synucleinopathies, are connected with either higher levels of normal alpha-synuclein or its mutant variants. The normal physiological role of Snca, however, has not yet been thoroughly explained. In fact, physiological Snca has been demonstrated to have a neuroprotective impact by inhibiting apoptosis induced by several types of apoptotic stimuli, or by regulating the expression of proteins involved in apoptotic pathways. Recently it has been demonstrated that up-regulation of alpha-synuclein in the dentate gyrus (a neurogenic niche where new neurons are generated throughout life) activates stem cells, in a model of premature neural aging. This model shows reduced expression of alpha-synuclein and reduced proliferation of stem cells, as is physiologically observed during aging. Exogenous alpha-synuclein in the dentate gyrus is able to rescue this defect. Moreover, alpha-synuclein also boosts the proliferation of dentate gyrus progenitor neural cells in wild-type young mice. Thus, alpha-synuclein represents an effector for neural stem and progenitor cell activation. Similarly, alpha-synuclein has been found to be required to maintain stem cells of the subventricular zone another neurogenic niche, in a cycling state.
Fury realizes that it was too easy to get in, just before his team is captured and stripped of their weapons. Viper reveals to him that she will release the virus even if they are paid, and locks Fury and his team in a freezer. Fury reveals that in place of his missing left eye, he keeps an explosive with which they can escape. Reaching Viper's control room, Fury and Viper fight until she gets hold of a gun and shoots him. However, it turns out to be Fury's Life Model Decoy. Fury incapacitates Zola and captures Viper, and Neville uses her telepathy to draw the code to abort the detonation from Viper's mind. The Helicarrier arrives and captures the rest of Hydra's forces, but Viper escapes with the body of her father. Fury decides to return to S.H.I.E.L.D. to counter the new threat of Hydra, while Viper is shown to have restored her father, Baron Wolfgang Von Strucker, to life.
The thiol group in proteins can usually be oxidized in the following ways, where GSH is glutathione, GSSG is glutathione disulfide, RSH is a protein containing a thiol group with R being the protein residue.2 RSH → RSSR + 2 H+ + 2 e−Disulfide formation stabilizes protein folded structure. Reduction of disulfinide protein can be done by thioredoxin or thioredoxin reductase. It common in secreted and membrane proteins that require a certain mechanical property to function, such as keratin. It is used for protein regulation, such as in the ferredoxin-thioredoxin system. RSH + GSSG ⇌ RSSG + GSH Glutathionylation is common in the cytosol and mitochondria. It can protect the reactive thiol, and it also can perform post-translational regulation of the protein. Reduction of glutathionylated protein can be done by GSH or glutaredoxin.
Sources: en.wikipedia.org
== History == Nedaplatin was developed in 1983 by Shionogi Pharmaceutical Company, as an alternative to cisplatin. It was first approved for use in Japan in 1995. Cisplatin was found to cause acute renal failure in approximately one third of subjects. Nedaplatin was found to cause less nephrotoxicity and gastrointestinal toxicity when compared to cisplatin, although still moderately present, yet it was proven to have the same effectivity. As renal toxicity is a severe limiting factor in clinical use, nedaplatin is already a better alternative to Cisplatin. Despite this, Japan is the only country with full clinical legislation of nedaplatin as of 2016.
The Global Carbon Budget 2021 concludes that fossil CO2 emissions rebounded by around +4.8% relative to 2020 emissions – returning to 2019 levels, identifies three major issues for improving reliable accuracy of monitoring, shows that China and India surpassed 2019 levels (by 5.7% and 3.2%) while the EU and the US stayed beneath 2019 levels (by 5.3% and 4.5%), quantifies various changes and trends, for the first time provides models' estimates that are linked to the official country GHG inventories reporting, and shows that the remaining carbon budget at 1. Jan 2022 for a 50% likelihood to limit global warming to 1.5 °C is 120 GtC (420 GtCO2) – or 11 years of 2021 emissions levels. Scientists propose and preliminarily evaluate a likely transgressed planetary boundary for green water in the water cycle, measured by root-zone soil moisture deviation from Holocene variability. A study published one day earlier integrates "green water" along with "blue water" into an index to measure and project water scarcity in agriculture for climate change scenarios. 27 April A lineage of H3N8 bird flu is found to infect humans for the first time, with a case reported in the Henan province of China. Months earlier, H5 strain bird flu viruses (HPAIv) have been detected in Canada and the US. A study extends global assessments of shares of species threatened by extinction with reptiles, which often play functional roles in their respective ecosystems, indicating at least 21% are threatened by extinction.
The APPI interface for LC–MS was developed simultaneously by Bruins and Syage in 2000. APPI is another LC–MS ion source/ interface for the analysis of neutral compounds that cannot be ionized using ESI. This interface is similar to the APCI ion source, but instead of a corona discharge, the ionization occurs by using photons coming from a discharge lamp. In the direct-APPI mode, singly charged analyte molecular ions are formed by absorption of a photon and ejection of an electron. In the dopant-APPI mode, an easily ionizable compound (dopant) is added to the mobile phase or the nebulizing gas to promote a reaction of charge-exchange between the dopant molecular ion and the analyte. The ionized sample is later transferred to the mass analyzer at high vacuum as it passes through small orifice skimmers.
Journalist and crime reporter John van den Heuvel was targeted by the Moroccan mafia after he made numerous statements about the workings of their criminal activities. In June 2018, the headquarter of the Dutch newspaper Panorama was attacked by a rocket launcher after they published articles on the Moroccan mafia. Shortly afterwards, the headquarter of another Dutch news-outlet De Telegraaf was attacked by a car, which was rammed into the office and set on fire afterwards. John van den Heuvel, who worked for De Telegraaf in the past, delivered his personal opinion on Dutch television by evoking the name of the criminal who was allegedly responsible:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.